ROS1 and non-small cell lung carcinoma: All the patients who were analyzed for clinical outcomes from first-line crizotinib met the following criteria: (1) pathologically-confirmed NSCLC, (2) locally advanced/unresectable disease to advanced/metastatic disease; (3) ROS1 rearrangements identified by NGS, and (4) treatment with crizotinib in the first-line setting.